Objective: The aim of this studywas to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. Methods: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. Results: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6%) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97%, 93%, and 92% respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMNconsisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time ofmore than 5 years, and no malignancy was diagnosed. Conclusions: In IPMN lesions with low-risk features at baseline, the risk of progression tomalignancy after the first 5 years of follow-up wasminimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Moris, M., Raimondo, M., Woodward, TA., Skinner, VJ., Arcidiacono, PG., Petrone, MC., De Angelis, C., Manfrè, S., Carrara, S., Jovani, M., Fusaroli, P., & Wallace, MB. (2017). International intraductal papillary mucinous neoplasms registry: Long-term results based on the new guidelines. Pancreas, 46(3), 306-310. https://doi.org/10.1097/MPA.0000000000000750